Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (73)	6/4/2002 6:32:45 PM
From: SemiBull	Read Replies (1) \| Respond to of 81

Westfield rates Valentis "speculative buy" NEW YORK, June 4 (Reuters) - Westfield Bakerink Brozak LLC began coverage on Tuesday of biotechnology company Valentis Inc. (NasdaqNM:VLTS - News) with a "speculative buy" rating, citing the company's strong intellectual property portfolio and promising drug delivery technology. Valentis develops synthetic systems that carry genes into the body to produce proteins that fight disease. Most gene delivery systems use viruses to carry desired proteins into the body. Eventually, the body is likely to develop resistance to the virus, said analyst Stephen Brozak. By using a synthetic system, patients can be repeatedly injected without fear of an adverse immune response, he said. "It's a delivery system which has multiple applications for every drug company out there." The company's first product, which is still in early stages of development, is directed at vascular disease. The aim is to promote the formation of new blood vessels in patients whose leg vessels have closed or are clogged. The company also plans to develop the product for use in heart disease. "Our only trepidation" about the company, said Brozak, comes from the "problematic capital markets landscape and how long its uncertainty will last."